

**Amendments to the Specification**

Please amend the specification as follows in accordance with 37 C.F.R. § 121.

Please replace the paragraph on page 5, lines 15-23, with the following amended paragraph:

-- Pharmaceutical formulations of the invention typically comprise an active compound selected from the group consisting of compounds that specifically bind to EMAP II (e.g., an antibody as described above), compounds that inhibit the expression of EMAP II, and EMAP II receptor antagonists; and a pharmaceutically acceptable carrier. ~~Since the N-terminal sequence obtained from the purified EMAP II is encoded by an internal sequence of the EMAP II clone, it was predicted that mature EMAP II (e.g., SEQ ID NO:5) results from processing from a larger polypeptide (e.g., SEQ ID NO:4) (see Stern et al., U.S. Patent No. 5,641,867, incorporated by reference herein).~~ Any pharmaceutically acceptable carrier may be employed, such as sterile saline solution, sterile water, etc. The active compound is included in the pharmaceutically acceptable carrier in any suitable amount, such as between about .001, .005 or .01 percent by weight to about 10, 20, 50 or 90 percent by weight by weight, or more. --